Navigation Links
NCCN Updates Guidelines for Central Nervous System (CNS) Cancers
Date:5/18/2009

NCCN recently updated the NCCN Guidelines for Central Nervous System (CNS) Cancers. Important new updates include the recommendation to use bevacizumab as a single agent for recurrent glioblastoma multiforme in CNS cancers, the integration of a patient's Karnofsky Performance Status (KPS) score into treatment decisions, and an adjusted age range for adjuvant therapy options in patients with low grade gliomas.

FORT WASHINGTON, Pa., May 18 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) announces new updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Central Nervous System (CNS) Cancers. These changes reflect leading developments in the treatment of patients with central nervous system cancers and represent the standard of clinical policy in oncology in both community and academic settings.

Primary and metastatic brain tumors are heterogeneous with diverse outcomes and management strategies. Because of this variability, the NCCN Guidelines note that prognostic features and treatment options for brain tumors must be carefully reviewed for each patient.

For patients with glioblastoma multiforme, the most common and most aggressive type of primary brain tumor, the updated NCCN Guidelines now recommend bevacizumab (Avastin(R), Genentech/Roche) as a single agent without irinotecan (Camptosar(R), Pfizer) for recurrence/salvage therapy. Previously, bevacizumab was only an option when used in combination with irinotecan.

Another noteworthy change in the updated NCCN Guidelines for patients with glioblastoma multiforme is the integration of a patient's Karnofsky Performance Status (KPS) score into the recommendation for adjuvant therapy. A KPS score is a standard way of measuring the ability of patients to perform ordinary tasks; the higher the score, the better the patient is able to carry out daily activities.

The new NCCN Guidelines adjusted the age range for patients with specific low grade gliomas who may consider fractionated external beam radiation therapy or chemotherapy as additional options to observation following maximal safe resection to 40 years and over. Previously, patients 45 and older were considered candidates for these adjuvant treatment options. For those under the age of 40, the NCCN Guidelines continue to recommend that patients remain under observation without any adjuvant therapy.

NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines are available free of charge at NCCN.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

For more information on NCCN, please visit NCCN.org.


'/>"/>
SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates
2. Carriage Services Updates Company & Investment Profile
3. Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
4. Cities Rapidly Turning to Nixle as Communications Platform for Swine Flu Updates; Outbreak Exemplifies Need for Secure, Trusted Communications
5. Nobel Laureate Celebrates With Thomson Reuters, Drs. Clotet and Gatell Ten Years of HIV Updates
6. BullMarket.com Updates Outlook on Medical Device and Equipment Stocks
7. NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus
8. Carriage Services Updates Company & Investment Profile
9. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
10. NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma
11. New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkins Lymphomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... ... full range of emergency dental care at his office, Antoine Dental Center. Emergency ... experience dental emergencies, they are at risk for serious complications and often experience ...
(Date:2/19/2017)... ... February 19, 2017 , ... The Citadel’s new Swain Department ... being led by Amelia Joseph, Ph.D. Joseph was engaged by the college as a ... department in early 2016. After a nation-wide search, she was selected to head the ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — ... looking to reduce their regulatory burden? Pay dividends in enhanced and predictable ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion ... Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... Users can pick and choose from hand-crafted trend-setting designs with smooth animations that ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy ... electronic prescribing of controlled and non-controlled substances plus the ability to manage orders ... the United States now accept electronic prescriptions, according to the Office of the ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... New York , February 20, 2017 ... regularized absorption of calcium and phosphorous minerals in one,s ... of vitamin D ingredients in maintaining a healthy composition ... medicines containing vitamin D ingredients is growing in the ... advantage of consuming vitamin D ingredients for treatment of ...
(Date:2/19/2017)... 19, 2017  nThrive™, an independent Patient-to-Payment? solutions ... thought leadership at the 2017 HIMSS Conference. The ... award from KLAS. nThrive will host ... how market trends shape the holistic, integrated revenue ... comprehensive Patient Access solution. The panel will reveal ...
(Date:2/18/2017)... PORT WASHINGTON, N.Y. , Feb. 17, 2017 ... law firm dedicated to protecting the rights of ... device problems have prompted regulators to call for ... events in 1990. Safety concerns involving ... and Drug Administration (FDA) to investigate how hospitals ...
Breaking Medicine Technology: